Cyclacel Pharmaceuticals Files S-1 for Securities Registration
Ticker: BGMSP · Form: S-1 · Filed: Apr 25, 2025 · CIK: 1130166
Sentiment: neutral
Topics: s-1, registration-statement, pharmaceuticals, sec-filing
TL;DR
Cyclacel just filed an S-1, looks like they're gearing up to sell more stock.
AI Summary
Cyclacel Pharmaceuticals, Inc. filed an S-1 registration statement on April 25, 2025, to register securities under the Securities Act of 1933. The company, formerly known as XCYTE THERAPIES INC, is incorporated in Delaware and has its principal executive offices in Kuala Lumpur, Malaysia, with a business address in Berkeley Heights, NJ. The filing indicates a potential offering of securities, though specific dollar amounts or dates for the offering are not detailed in this initial document.
Why It Matters
This S-1 filing signals Cyclacel Pharmaceuticals' intent to raise capital through the sale of securities, which could impact its future operations, research and development, and stock value.
Risk Assessment
Risk Level: medium — S-1 filings often precede stock offerings, which carry inherent risks related to market conditions, company performance, and dilution.
Key Numbers
- 333-286754 — SEC File Number (Identifies the specific SEC registration)
- 93-2403210 — I.R.S. Employer Identification Number (Company's tax identification number)
Key Players & Entities
- Cyclacel Pharmaceuticals, Inc. (company) — Registrant
- XCYTE THERAPIES INC (company) — Former company name
- 200 Connell Drive, Suite 1500, Berkeley Heights, NJ 07922 (location) — Business and Mail Address
- Level 10, Tower 11, Avenue 5, The Horizon Bangsar South City, No. 8, Jalan Kerinchi, 59200, Kuala Lumpur, Malaysia (location) — Principal Executive Offices
- Datuk Dr. Doris Wong Sing Ee (person) — Chief Executive Officer
- April 25, 2025 (date) — Filing date
FAQ
What is the purpose of this S-1 filing?
The S-1 filing is a registration statement under the Securities Act of 1933, indicating Cyclacel Pharmaceuticals, Inc.'s intent to offer securities for sale.
When was this S-1 filing submitted?
The S-1 filing was submitted to the SEC on April 25, 2025.
Where are Cyclacel Pharmaceuticals, Inc.'s principal executive offices located?
The principal executive offices are located at Level 10, Tower 11, Avenue 5, The Horizon Bangsar South City, No. 8, Jalan Kerinchi, 59200, Kuala Lumpur, Malaysia.
What was Cyclacel Pharmaceuticals, Inc.'s former name?
The company's former name was XCYTE THERAPIES INC, with a date of name change on December 18, 2000.
Who is the Chief Executive Officer of Cyclacel Pharmaceuticals, Inc.?
Datuk Dr. Doris Wong Sing Ee is the Chief Executive Officer of Cyclacel Pharmaceuticals, Inc.
Filing Details
This Form S-1 (Form S-1) was filed with the SEC on April 25, 2025 by Datuk Dr. Doris Wong Sing Ee regarding Cyclacel Pharmaceuticals, Inc. (BGMSP).